<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574573</url>
  </required_header>
  <id_info>
    <org_study_id>PS0054</org_study_id>
    <nct_id>NCT01574573</nct_id>
  </id_info>
  <brief_title>Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study</brief_title>
  <official_title>Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Biomedical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Biomedical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By affecting the gastroesophageal pressure gradient, obesity predisposes to reflux of gastric
      contents. The investigators hypothesized that the loss of weight will decrease this gradient
      and as a result decrease the severity and frequency of GERD symptoms. GERD negatively affects
      health related quality of life. Since loss of weight may decrease gastroesophageal reflux,
      the investigators hypothesized that it obesity contributes to poor quality of life in GERD
      subjects and losing weight should also favorably impact and improve quality of life in GERD
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current proposal is a prospective, observational cohort study This study aims to
      determine the impact of structured weight loss (MOVE program) on GERD symptoms in overweight
      and obese veterans enrolled in a MOVE program. Successful weight loss will be defined as loss
      of 10% or higher baseline weight at 6 months follow up. Cases will be defined as subjects who
      achieved successful weight loss and controls as those who did not. GERD symptoms in subjects
      who lose weight (cases) will be compared to those with no weight loss (controls). Validated
      GERQ, RDQ and QOLRAD questionnaires will be used to assess prevalence of GERD symptoms, QOL
      and impact of weight loss on these symptoms. All MOVE participants will complete a validated
      GERQ, RDQ and QOLRAD questionnaires at baseline MOVE clinic visit and RDQ and QOLRAD during
      their follow up visits. Patient's total RDQ scores at baseline and follow up visits will be
      used to determine change in frequency and severity of GERD symptoms with weight loss,
      similarly change in the total QOLRAD questionnaire scores from baseline will be used to
      assess change in HRQOL with weight loss. Apart from information provided in MOVE!23, GERQ,
      RDQ and QOLRAD questionnaires, relevant information pertaining to obesity and GERD
      association will be obtained from patient's computerized medical records.

      The impact of weight loss on GERD symptoms will be assessed. The impact of weight loss on QOL
      and GERD medication usage among MOVE participants will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to lack of recruitment
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Weight loss on GERD symptoms</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of weight loss on quality of life and GERD symptoms</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>GERD</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese individuals with weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Self support, group sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese individuals without weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>self support, group sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self support, group sessions</intervention_name>
    <description>Self support,group sessions</description>
    <arm_group_label>Obese individuals with weight loss</arm_group_label>
    <arm_group_label>Obese individuals without weight loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be a Kansas City Veterans Hospital patient who is enrolled in the MOVE weight
             loss program

          -  Patients with a BMI &gt; 25 with associated coâ€”morbid medical conditions such as
             diabetes, high blood pressure, high cholesterol, arthritis, heart disease, low back
             pain, sleep apnea, or other obesity associated condition.

          -  Enrollment in MOVE program is optional for patients with a BMI &gt; 25 with no co-morbid
             medical conditions.

          -  Enrollment for patients 70 years or older with BMI &gt; 25 is optional and requires
             mandatory medical clearance prior to beginning new physical activity and closer
             nutritional supervision to minimize protein, vitamin and mineral deficiencies.

        Exclusion Criteria:

          -  Active cancer other than non-melanoma skin cancer

          -  End stage COPD, congestive heart failure

          -  End stage neurologic disorder (Parkinson's, ALS, MS)

          -  Long-term care facility resident

          -  End stage renal disease

          -  Moderate to severe cognitive impairment (dementia, post-stroke)

          -  Active psychosis or substance abuse

          -  AIDS (except asymptomatic HIV infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prateek Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Topeka VA Medical Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May;54(5):710-7. Review.</citation>
    <PMID>15831922</PMID>
  </reference>
  <reference>
    <citation>Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol. 2004 Jun;57(6):580-9.</citation>
    <PMID>15246126</PMID>
  </reference>
  <reference>
    <citation>McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996 Apr;38(4):481-6.</citation>
    <PMID>8707073</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001 Jul;96(7):1998-2004.</citation>
    <PMID>11467624</PMID>
  </reference>
  <reference>
    <citation>Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003 Oct 15;18(8):767-76.</citation>
    <PMID>14535869</PMID>
  </reference>
  <reference>
    <citation>Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56.</citation>
    <PMID>9136821</PMID>
  </reference>
  <reference>
    <citation>Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976 Nov;21(11):953-6.</citation>
    <PMID>984016</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005 Oct;100(10):2151-6.</citation>
    <PMID>16181362</PMID>
  </reference>
  <reference>
    <citation>El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26. Epub 2006 Dec 4. Review.</citation>
    <PMID>17142109</PMID>
  </reference>
  <reference>
    <citation>Fisher BL, Pennathur A, Mutnick JL, Little AG. Obesity correlates with gastroesophageal reflux. Dig Dis Sci. 1999 Nov;44(11):2290-4.</citation>
    <PMID>10573376</PMID>
  </reference>
  <reference>
    <citation>Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 Apr 5;295(13):1549-55.</citation>
    <PMID>16595758</PMID>
  </reference>
  <reference>
    <citation>Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, Harvey R. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol. 2003 Aug;32(4):645-50.</citation>
    <PMID>12913045</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwest Biomedical Research Foundation</investigator_affiliation>
    <investigator_full_name>PRATEEK SHARMA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>GERD</keyword>
  <keyword>Weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

